MedTrace Logo

Effects of Urinary Kallidinogenase in Acute Ischemic Stroke Patients With Abnormal Glucose Metabolism

NCT04020666 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 113

Last updated 2019-07-16

No results posted yet for this study

Summary

Urinary kallidinogenase may assist recovery acute ischemic stroke. This study evaluated the impact of urinary kallidinogenase on NIHSS score, modified Rankin scale (mRS) score and fasting glucose levels in patients with AIS combined with diabetes mellitus and impaired fasting glucose.

Conditions

  • Acute Ischemic Stroke
  • Abnormal Glucose Metabolism

Interventions

DRUG

Urinary Kallidinogenase

Sponsors & Collaborators

  • The Second Hospital of Hebei Medical University

    lead OTHER

Principal Investigators

  • Xiaopeng Wang, MD · The Second Hospital of Hebei Medical University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2017-10-31
Completion
2017-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04020666 on ClinicalTrials.gov